Publications by authors named "J H Chern"

Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization inhibitor. We assessed safety, activity and pharmacokinetics of the combination AR/bevacizumab (Bev) (ARB) versus weekly paclitaxel (wP)/Bev (PB) in patients with platinum resistant/refractory HGOC (prrHGOC).

View Article and Find Full Text PDF

Current CML treatments often suffer from undesired side effects. Herein we report the computation-assisted optimization of Bcr-Abl/C-Src dual kinase inhibitor. We surmised the improved toxicity profile was achieved via disrupted ligand-target binding.

View Article and Find Full Text PDF

Thousands of phonological word forms known to a speaker can be organised as a lexical network using the tools of network science. In these networks, nodes represent words and edges are placed between phonological neighbours. Previous work has shown that phonological networks of various languages have similar macrolevel network properties.

View Article and Find Full Text PDF
Article Synopsis
  • - Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder caused by mutations in certain genes, leading to the growth of benign tumors and significant neurological issues in affected individuals.
  • - Research using 3D brain organoids from TSC patients revealed that genetic variants disrupt critical processes like neurogenesis and synaptogenesis, which are linked to neurodevelopmental disorders such as autism and epilepsy.
  • - Findings show that the mutations in TSC interfere with communication between neurons and astrocytes, affecting synaptic transmission and brain network activity, with parallels observed in brain tissue from TSC patients.
View Article and Find Full Text PDF

Background And Objectives: Infectious intracranial aneurysms (IIAs) are rare cerebrovascular complications of infective endocarditis (IE) accounting approximatively for 0.5% to 6.5% of all aneurysms.

View Article and Find Full Text PDF